Clofibric acid

Clofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research[1][2][3][4][5][6][7][8][9].

Product Specifications

CAS Number

[882-09-7]

Product Name Alternative

Chlorofibrinic acid

UNSPSC

12352005

Hazard Statement

H302

Target

Bacterial; PPAR; SOD

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Clofibric-acid.html

Purity

99.99

Solubility

DMSO : ≥ 100 mg/mL|H2O : 1 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O

Molecular Formula

C10H11ClO3

Molecular Weight

214.65

Precautions

H302

References & Citations

[1]Forman BM, et, al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997 Apr 29;94 (9) :4312-7.|[2]Salgado R, et, al. Biodegradation of clofibric acid and identification of its metabolites. J Hazard Mater. 2012 Nov 30;241-242:182-9.|[3]Kawashima Y, et, al. Increased activity of stearoyl-CoA desaturation in liver from rat fed clofibric acid. Biochim Biophys Acta. 1982 Dec 13;713 (3) :622-8.|[4]Yokoyama Y, et al. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther. 2007 Apr;6 (4) :1379-86.|[5]Bécuwe P, et al. Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line. Biochem Pharmacol. 1999 Sep 15;58 (6) :1025-33.|[6]Blaauboer B J, et al. The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochemical Pharmacology, 1990, 40 (3) : 521-528.|[7]Cleary MP, et al. Effect of long-term clofibric acid treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats. Atherosclerosis. 1987 Jul;66 (1-2) :107-12.|[8]Balagué CE, et al. Clofibric and ethacrynic acids prevent experimental pyelonephritis by Escherichia coli in mice. FEMS Immunol Med Microbiol. 2004 Nov 1;42 (3) :313-9.|[9]Yamakawa Y, et al. A single pretreatment with clofibric acid attenuates carbon tetrachloride-induced necrosis, but not steatosis, in rat liver. Food Chem Toxicol. 2020 Nov;145:111591.